Portal de Periódicos da CAPES

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

2020; Massachusetts Medical Society; Volume: 383; Issue: 2 Linguagem: Inglês

10.1056/nejmoa1917006

1533-4406

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima,

Allergic Rhinitis and Sensitization

Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.